<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02171546</url>
  </required_header>
  <id_info>
    <org_study_id>1160.75</org_study_id>
    <nct_id>NCT02171546</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability of Dabigatran Etexilate Capsules With and Without Quinidine Sulfate Tablets and to Measure the Effect of Quinidine on the Absorption of Fexofenadine in Healthy Male and Female Volunteers</brief_title>
  <official_title>A Two-part Study to Determine the Relative Bioavailability of Dabigatran Etexilate 150 mg Bid (Capsules) With and Without 600 mg Quinidine Sulfate Tablets (Part 1) and to Measure the Effect of Quinidine as a Probe Inhibitor of P-glycoprotein on the Absorption of Fexofenadine, a Probe Substrate of P-glycoprotein (Part 2) in Healthy Male and Female Volunteers (an Open-label, Randomised, Two Times Two-way Crossover Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Part 1: To investigate the effect of quinidine, a P-glycoprotein (P-gp) probe inhibitor on
      the bioavailability of dabigatran etexilate,

      Part 2: To determine the effect of quinidine on the bioavailability of fexofenadine, a probe
      substrate for P-gp
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>November 2007</start_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCτ,ss (area under the concentration-time curve of dabigatran in plasma at steady state over one dosing interval)</measure>
    <time_frame>Before dose, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00 and 12:00 hours after dosing on day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss (maximum concentration of dabigatran in plasma at steady state)</measure>
    <time_frame>Before dose on day 1, day 2, before dose, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 48:00 hours after dosing on Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ (area under the concentration-time curve of fexofenadine in plasma over the time interval from 0 to infinity)</measure>
    <time_frame>Before dose, 0:30, 1:00,1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 48:00 hours after dosing on day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum measured concentration of fexofenadine in plasma)</measure>
    <time_frame>Before dose, 0:30, 1:00,1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 48:00 hours after dosing on day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz,ss (area under the concentration-time curve of dabigatran in plasma from the time point 0 after the last dose at steady state to the last quantifiable dabigatran plasma concentration within the uniform dosing interval τ)</measure>
    <time_frame>0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24 and 48 hours after dosing on day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tz,ss (time of last measurable concentration of dabigatran in plasma within the dosing interval τ at steady state)</measure>
    <time_frame>0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24 and 48 hours after dosing on day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax,ss (time from last dosing to the maximum concentration of dabigatran in plasma at steady state)</measure>
    <time_frame>0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24 and 48 hours after dosing on day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/Fss (apparent clearance of dabigatran in the plasma at steady state)</measure>
    <time_frame>Before dose on day 1, day 2, before dose, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 48:00 hours after dosing on Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss (minimum measured concentration of dabigatran in plasma at steady state)</measure>
    <time_frame>Before dose on day 1, day 2, before dose, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 48:00 hours after dosing on Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cavg (average concentration of dabigatran at steady state)</measure>
    <time_frame>Before dose on day 1, day 2, before dose, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 48:00 hours after dosing on Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C10,2 (total dabigatran concentration 10 hours after the second dabigatran etexilate administration)</measure>
    <time_frame>Day 2, 22 hours after the first dose on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmin,ss (time from last dosing to the minimum concentration of dabigatran in plasma at steady state over a uniform dosing interval τ)</measure>
    <time_frame>Before dose on day 1, day 2, before dose, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 48:00 hours after dosing on Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTpo,ss (mean residence time of dabigatran in the body at steady state after oral administration)</measure>
    <time_frame>Before dose on day 1, day 2, before dose, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 48:00 hours after dosing on Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/Fss (apparent volume of distribution of dabigatran during the terminal phase λz at steady state following an extravascular administration)</measure>
    <time_frame>Before dose on day 1, day 2, before dose, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 48:00 hours after dosing on Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration of quinidine in plasma)</measure>
    <time_frame>Pre-dose, 0:30, 1:00, 2:00, 3:00, 4:00, 6:00, 8:00, 11:00, 13:00, 25:00 and 49 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞ (area under the concentration-time curve of quinidine in plasma over the time interval from 0 to infinity)</measure>
    <time_frame>Pre-dose, 0:30, 1:00, 2:00, 3:00, 4:00, 6:00, 8:00, 11:00, 13:00, 25:00 and 49 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of fexofenadine in plasma from the time point 0 after the last dose to the last quantifiable analyte plasma concentration within the uniform dosing interval τ)</measure>
    <time_frame>Before dose, 0:30, 1:00,1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 48:00 hours after dosing on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (time from last dosing to the maximum measured concentration of fexofenadine in plasma)</measure>
    <time_frame>Before dose, 0:30, 1:00,1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 48:00 hours after dosing on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½ (terminal half-life of fexofenadine in plasma)</measure>
    <time_frame>Before dose, 0:30, 1:00,1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 48:00 hours after dosing on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTpo (mean residence time of fexofenadine in the body after p.o. administration)</measure>
    <time_frame>Before dose, 0:30, 1:00,1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 48:00 hours after dosing on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F (apparent clearance of fexofenadine in plasma following extravascular administration)</measure>
    <time_frame>Before dose, 0:30, 1:00,1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 48:00 hours after dosing on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F (apparent volume of distribution of fexofenadine during the terminal phase λz following an extravascular dose)</measure>
    <time_frame>Before dose, 0:30, 1:00,1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 48:00 hours after dosing on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½ (terminal half-life of dabigatran in plasma at steady state)</measure>
    <time_frame>Before dose, 0:30, 1:00,1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 and 48:00 hours after dosing on day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cpre,ss (pre-dose concentration of dabigatran in plasma immediately before administration of the following dose at steady state)</measure>
    <time_frame>Before dose on day 3, day 4, and day 5</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dabigatran etexilate capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran etexilate capsules and quinidine sulfate tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fexofenadine tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fexofenadine and quinidine sulfate tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate capsules</intervention_name>
    <arm_group_label>Dabigatran etexilate capsules</arm_group_label>
    <arm_group_label>Dabigatran etexilate capsules and quinidine sulfate tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quinidine sulfate tablets</intervention_name>
    <arm_group_label>Dabigatran etexilate capsules and quinidine sulfate tablets</arm_group_label>
    <arm_group_label>Fexofenadine and quinidine sulfate tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fexofenadine tablets</intervention_name>
    <arm_group_label>Fexofenadine tablets</arm_group_label>
    <arm_group_label>Fexofenadine and quinidine sulfate tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males and females according to the following criteria: Based upon a complete
             medical history, including the physical examination, vital signs (BP, PR), 12-lead
             ECG, clinical laboratory tests ;

          2. Age ≥18 and Age ≤55 years;

          3. Body Mass Index (BMI) ≥18.5 and BMI &lt;30 kg/m2;

          4. Signed and dated written informed consent prior to admission to the study in
             accordance with GCP and the local legislation;

          5. If female of child-bearing potential, not be pregnant or breast feeding, nor plan to
             become pregnant for the duration of the study and for 2 months after receiving the
             last dose of study drug, and have a negative serum pregnancy test within 14 days of
             treatment, and prior to dosing;

          6. Females of child-bearing potential willing to use adequate contraception, defined as
             the use of hormonal (oral, injectable or implantable) or barrier method
             contraceptives, intrauterine device and agree to use the same method of contraception
             for at least 2 months after drug administration. Women who have undergone a total
             hysterectomy, have a history of bilateral tubal ligation or are at least 2 years
             post-menopausal are not considered to be of child-bearing potential.

        Exclusion Criteria:

          1. Any finding of the medical examination (including BP, PR and ECG) deviating from
             normal and of clinical relevance;

          2. Any evidence of a clinically relevant concomitant disease;

          3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders;

          4. Surgery of the gastrointestinal tract (except appendectomy);

          5. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders;

          6. History of relevant orthostatic hypotension, fainting spells or blackouts;

          7. Chronic or relevant acute infections;

          8. History of relevant allergy/hypersensitivity (including allergy to drug or its
             excipients);

          9. Intake of drugs with a long half-life (&gt;24 hours) within at least one month or less
             than 10 half-lives of the respective drug prior to administration or during the trial;

         10. Use of drugs which might reasonably influence the results of the trial or that prolong
             the QT/QTc interval based on the knowledge at the time of protocol preparation within
             10 days prior to administration or during the trial;

         11. Participation in another trial with an investigational drug within two months prior to
             administration or during the trial;

         12. Smoker (&gt;10 cigarettes or &gt;3 cigars or &gt;3 pipes/day);

         13. Inability to refrain from smoking on trial days;

         14. Alcohol abuse (more than 60 g/day);

         15. Drug abuse;

         16. Blood donation (more than 100 mL within four weeks prior to administration or during
             the trial);

         17. Excessive physical activities (within one week prior to administration or during the
             trial);

         18. Any laboratory value outside the reference range that is of clinical relevance;

         19. Inability to comply with dietary regimen of trial site;

         20. A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a
             QTc interval &gt;450 ms);

         21. A history of additional risk factors for Torsades de Pointes (e.g., heart failure,
             hypokalemia, family history of Long QT Syndrome);

         22. Taking drugs which are known P-gp inhibitors or inducers (verapamil, phenothiazine
             antipsychotics, erythromycin, antifungal drugs or St. John´s Wort) within the last 4
             weeks before screening;

         23. Chronic use of oral contraception containing ethinyl estradiol as the only method of
             contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <last_update_submitted>June 20, 2014</last_update_submitted>
  <last_update_submitted_qc>June 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Quinidine</mesh_term>
    <mesh_term>Fexofenadine</mesh_term>
    <mesh_term>Terfenadine</mesh_term>
    <mesh_term>Quinidine gluconate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

